Logo

SLRX

Salarius Pharmaceuticals, Inc.

SLRX

Salarius Pharmaceuticals, Inc. • NASDAQ
$0.94 ▲ 1.10% (+0.01)
Market Cap $5.48 M
52w High $108.00
52w Low $0.71
Dividend Yield 0%
P/E -0.04
Volume 277.35K
Outstanding Shares 5.86M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $894.024K ▼ $-873.467K ▲ 0% $-1.81 ▲ $-872.361K ▲
Q2-2025 $0 $965.565K ▼ $-957.825K ▲ 0% $-6.75 ▲ $-964.459K ▲
Q1-2025 $0 $1.719M ▲ $-1.71M ▼ 0% $-15.45 ▲ $-1.718M ▼
Q4-2024 $0 $1.489M ▲ $-1.464M ▼ 0% $-22.8 ▼ $-1.488M ▼
Q3-2024 $0 $1.006M $-972.121K 0% $-11.4 $-1.005M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $4.81M ▲ $6.097M ▲ $1.849M ▼ $4.248M ▲
Q2-2025 $794.886K ▼ $1.393M ▼ $2.223M ▼ $-829.724K ▼
Q1-2025 $1.798M ▼ $2.339M ▼ $2.278M ▲ $61.866K ▼
Q4-2024 $2.435M ▼ $3.023M ▼ $1.511M ▲ $1.512M ▼
Q3-2024 $3.284M $3.859M $934.581K $2.925M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-873.467K ▲ $-1.647M ▼ $-200K ▼ $5.861M ▲ $4.015M ▲ $-1.647M ▼
Q2-2025 $-957.825K ▲ $-862.297K ▲ $0 $-141.197K ▼ $-1.003M ▼ $-862.297K ▲
Q1-2025 $-1.71M ▼ $-1.182M ▼ $0 $545.566K ▲ $-636.148K ▲ $-1.182M ▼
Q4-2024 $-1.464M ▼ $-742.518K ▲ $0 $-106.983K ▼ $-849.501K ▼ $-742.518K ▲
Q3-2024 $-972.121K $-1.357M $0 $1.368M $11.206K $-1.357M

Revenue by Products

Product Q1-2021Q1-2024Q2-2024Q3-2024
Grant
Grant
 $0 ▲$0 ▲$0 ▲$0 ▲
Grant CastrationResistant Prostate Study
Grant CastrationResistant Prostate Study
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Salarius looks like a classic early‑stage biotech: it has essentially no commercial revenue and its income statement is driven almost entirely by research and operating expenses. Losses have been steady over the past few years rather than exploding higher, which suggests some cost discipline, but the company is still firmly in the “spending to develop” phase. Reported per‑share losses appear very large because of repeated reverse stock splits, so headline earnings per share figures are more about past capital structure changes than a sudden collapse in the business. Overall, this is a pre‑revenue, R&D‑heavy income profile with ongoing operating losses and a long path to potential profitability that depends on successful drug development.

Balance Sheet

Balance Sheet The balance sheet is very light, with a small asset base made up mostly of cash and very little in the way of physical assets or inventory, which is typical for a platform‑based biotech. The company reports no debt, which reduces financial leverage risk but also means it depends mainly on equity funding or partnerships to support operations. Shareholders’ equity is thin and has trended down with losses, reflecting the strain of funding R&D without revenue. Multiple reverse stock splits over recent years underline both the small market capitalization and the challenge of maintaining listing standards and investor confidence. Financially, Salarius is lean and simple, but also fragile, with limited cushion if results or funding fall short.

Cash Flow

Cash Flow Cash flow is negative from operations, in line with a company that is spending on research while generating no product sales. Free cash flow is also negative but not heavily influenced by capital spending, since the business model is based more on intellectual property and external labs than on heavy equipment. This means cash burn is primarily driven by payroll, trials, and development costs. Sustaining the current strategy will likely require periodic new funding or partnerships unless there is a shift to upfront payments or grants. The key question for cash flow is how quickly the new pipeline can attract external capital or collaborations to offset ongoing outflows.

Competitive Edge

Competitive Edge Salarius is a very small player in a sector dominated by large pharmaceutical companies and better‑funded biotechs, but it is trying to carve out a niche with its AI‑driven peptide conjugate platform. Its focus on broad‑spectrum antivirals and targeted peptide drug conjugates gives it a differentiated story compared with traditional small‑molecule or antibody developers. The merger with Decoy Therapeutics brings specialized know‑how and a proprietary platform, which can serve as a technical moat if it continues to generate attractive drug candidates quickly. However, the company’s scale, limited resources, and early stage of many programs mean that competitive strength remains more potential than proven, and larger players could move into similar areas if early results look compelling.

Innovation and R&D

Innovation and R&D Innovation is the core of Salarius’s value proposition. The IMP³ACT platform marries machine learning with peptide chemistry to design and build drug candidates far faster than traditional methods, particularly for peptide conjugates and fusion inhibitors. The lead programs—a pan‑coronavirus antiviral, a single antiviral aimed at influenza, COVID‑19, and RSV, and peptide drug conjugates for gastrointestinal cancers—are ambitious and target areas of clear medical need. The ability to repurpose legacy assets like SP‑3164 into peptide‑based PROTACs, and to extract value from ongoing trials such as seclidemstat, suggests a willingness to reuse and integrate past work rather than start from scratch. The main risk is execution: these are early, complex programs that must still clear preclinical, regulatory, and clinical hurdles before the R&D story translates into tangible products or deals.

Summary

Salarius is in the midst of a major reinvention from a traditional oncology‑focused biotech into an AI‑enabled peptide therapeutics platform company. Financially, it looks like a typical pre‑revenue biotech: small, loss‑making, reliant on external capital, and operating with a thin but debt‑free balance sheet. The business risk is high because there is no commercial cushion if R&D setbacks occur, and repeated reverse splits highlight past dilution and market pressure. On the other hand, the strategic pivot and the IMP³ACT platform give the company a clearer technological identity, with programs aimed at broad‑spectrum antivirals and targeted oncology that could be attractive if early data are strong. Going forward, the story will hinge on the company’s ability to turn this innovative platform into concrete milestones—such as regulatory filings, partnerships, or compelling preclinical and clinical results—before financial constraints become too tight.

NEWS

November 19, 2025 · 2:42 PM UTC

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Read more

November 13, 2025 · 8:45 AM UTC

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Read more

November 11, 2025 · 9:18 AM UTC

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Read more

October 13, 2025 · 8:45 AM UTC

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Read more